Key Takeaways
- • İş Private Equity commits $39 million to fund Gökhan Hotamışlıgil's biological research lab at Harvard's T.H. Chan School of Public Health, with an additional undisclosed investment earmarked for drug candidates emerging from the lab.
- • Deal structure bridges academic research and commercialization: The arrangement simultaneously funds the Harvard laboratory and launches a new biotech company called Enlila to develop therapies for metabolic conditions, creating a hybrid funding model.
- • Universities view arrangement as template for federal funding gap: Harvard administrators cite this deal as a potential blueprint for academic institutions nationwide as they navigate severe research financing cuts under Trump administration policies.
- • Turkish İşbank Group backing signals international capital entering U.S. academic research: İş Private Equity, a subsidiary of Turkey's İşbank Group, represents foreign institutional capital seeking exposure to high-value biomedical research pipelines.
- • Modest deal size reflects broader reshaping of academic research finance: At $39 million for core lab funding, the arrangement is relatively small in investment banking terms but signals fundamental shifts in how universities fund scientific research amid federal budget pressures.
Summary
İş Private Equity, the investment arm of Turkey's İşbank Group, has committed $39 million to finance a biological research laboratory at Harvard University directed by Gökhan Hotamışlıgil, a professor of genetics and metabolism at the T.H. Chan School of Public Health. The announcement, made Monday, represents an unconventional partnership between a private equity firm and academic research infrastructure at a time when federal funding for university science has contracted sharply.
The transaction includes dual mechanisms: direct capital for the Harvard laboratory alongside an undisclosed secondary investment in drug candidates that advance to clinical development. The arrangement simultaneously establishes Enlila, a newly formed biotech company tasked with developing therapeutic candidates focused on metabolic diseases. This structure allows the private equity firm to gain exposure to translational research while providing the academic institution with capital insulation from federal appropriations volatility.
Harvard administrators have characterized the deal as a potential replicable model for other research institutions navigating unprecedented federal funding reductions. The timing is significant: the Trump administration's research cuts have created acute financing pressure across the university sector, forcing academic institutions to explore alternative capital sources. This arrangement between a major university and a foreign private equity firm reflects the broader institutional pivot toward private sector partnerships as traditional federal research funding mechanisms face contraction.
While the $39 million commitment represents a relatively modest transaction by investment banking standards, it signals a structural shift in how elite research institutions are accessing capital. The involvement of an international institutional investor also underscores growing global interest in U.S. academic research pipelines, particularly in high-value therapeutic development areas such as metabolic disease treatment.
The deal remains limited in scope—affecting a single laboratory and specific therapeutic focus area. However, its emergence during a period of acute federal funding pressure suggests that similar private equity-academic partnerships may proliferate as universities seek to sustain research operations outside traditional government grant mechanisms.
The transaction includes dual mechanisms: direct capital for the Harvard laboratory alongside an undisclosed secondary investment in drug candidates that advance to clinical development. The arrangement simultaneously establishes Enlila, a newly formed biotech company tasked with developing therapeutic candidates focused on metabolic diseases. This structure allows the private equity firm to gain exposure to translational research while providing the academic institution with capital insulation from federal appropriations volatility.
Harvard administrators have characterized the deal as a potential replicable model for other research institutions navigating unprecedented federal funding reductions. The timing is significant: the Trump administration's research cuts have created acute financing pressure across the university sector, forcing academic institutions to explore alternative capital sources. This arrangement between a major university and a foreign private equity firm reflects the broader institutional pivot toward private sector partnerships as traditional federal research funding mechanisms face contraction.
While the $39 million commitment represents a relatively modest transaction by investment banking standards, it signals a structural shift in how elite research institutions are accessing capital. The involvement of an international institutional investor also underscores growing global interest in U.S. academic research pipelines, particularly in high-value therapeutic development areas such as metabolic disease treatment.
The deal remains limited in scope—affecting a single laboratory and specific therapeutic focus area. However, its emergence during a period of acute federal funding pressure suggests that similar private equity-academic partnerships may proliferate as universities seek to sustain research operations outside traditional government grant mechanisms.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.